{"id":"mifamurtide","rwe":[{"pmid":"41534017","year":"2026","title":"Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.","finding":"","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","studyType":"Clinical Study"},{"pmid":"41534000","year":"2026","title":"Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.","finding":"","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","studyType":"Clinical Study"},{"pmid":"40960554","year":"2025","title":"The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide.","finding":"","journal":"Medical oncology (Northwood, London, England)","studyType":"Clinical Study"},{"pmid":"40825172","year":"2025","title":"Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.","finding":"","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","studyType":"Clinical Study"},{"pmid":"40711479","year":"2025","title":"Tumor Immune Microenvironment-Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial.","finding":"","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","studyType":"Clinical Study"}],"tags":[{"label":"mifamurtide","category":"class"},{"label":"Peptide","category":"modality"},{"label":"Nucleotide-binding oligomerization domain-containing protein 2","category":"target"},{"label":"NOD2","category":"gene"},{"label":"L03AX15","category":"atc"},{"label":"Active","category":"status"},{"label":"Osteosarcoma of bone","category":"indication"},{"label":"Takeda France SAS","category":"company"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":60.336,"date":"","count":10,"signal":"Drug clearance decreased","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=60)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Takeda France SAS","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MIFAMURTIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:22:05.018291+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Mifamurtide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:22:18.360895+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:22:17.011044+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T01:22:05.036765+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:22:17.773047+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Nucleotide-binding oligomerization domain-containing protein 2 other","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:22:18.360552+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107354/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:22:18.266462+00:00"}},"allNames":"mepact","offLabel":[],"synonyms":["MTP-PE","mifamurtide hydrate","muramyl tripeptide phosphatidyl ethanolamine","mepact","mifamurtide sodium","mifamurtide","junovan","L-MTP-PE"],"timeline":[{"date":"2009-03-06","type":"positive","source":"DrugCentral","milestone":"EMA approval (Takeda France SAS)"}],"approvals":[{"date":"2009-03-06","orphan":true,"company":"Takeda France SAS","regulator":"EMA"}],"brandName":"Mepact","ecosystem":[{"indication":"Osteosarcoma of bone","otherDrugs":[{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"methotrexate","slug":"methotrexate","company":"Dava Pharms Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Nucleotide-binding oligomerization domain-containing protein 2","targets":[{"gene":"NOD2","source":"DrugCentral","target":"Nucleotide-binding oligomerization domain-containing protein 2","protein":"Nucleotide-binding oligomerization domain-containing protein 2"}],"modality":"Peptide","drugClass":"mifamurtide","explanation":"","oneSentence":"","technicalDetail":"Mepact, a mifamurtide, acts as an immunomodulator by activating the NOD2 receptor, which triggers a cascade of immune responses to combat cancer cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Mifamurtide","title":"Mifamurtide","extract":"Mifamurtide is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which is lethal in over half of cases. The drug was approved in Europe in March 2009.","wiki_history":"== History ==\nThe drug was invented by Ciba-Geigy (now Novartis) in the early 1980s and sold to Jenner Biotherapies in the 1990s. In 2003, IDM Pharma bought the rights and developed it further. IDM Pharma was acquired by Takeda along with mifamurtide in June 2009.\n\nMifamurtide had already been granted orphan drug status by the U.S. Food and Drug Administration (FDA) in 2001, and the European Medicines Agency (EMA) followed in 2004. It was approved in the 27 European Union member states plus Iceland, Liechtenstein, and Norway by a centralized marketing authorization in March 2009. The drug was denied approval by the FDA in 2007. Mifamurtide has been licensed by the EMA since March, 2009."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2960","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MIFAMURTIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Mifamurtide","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T14:31:41.683269","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:22:20.117429+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"pegademase","drugSlug":"pegademase","fdaApproval":"1990-03-21","relationship":"same-class"},{"drugName":"glatiramer acetate","drugSlug":"glatiramer-acetate","fdaApproval":"1996-12-20","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"histamine","drugSlug":"histamine","fdaApproval":"1939-04-25","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"plerixafor","drugSlug":"plerixafor","fdaApproval":"2008-12-15","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"elapegademase","drugSlug":"elapegademase","fdaApproval":"2018-10-05","relationship":"same-class"}],"genericName":"mifamurtide","indications":{"approved":[{"name":"Osteosarcoma of bone","source":"DrugCentral","snomedId":307576001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pegademase","brandName":"pegademase","genericName":"pegademase","approvalYear":"1990","relationship":"same-class"},{"drugId":"glatiramer-acetate","brandName":"glatiramer acetate","genericName":"glatiramer acetate","approvalYear":"1996","relationship":"same-class"},{"drugId":"histamine","brandName":"histamine","genericName":"histamine","approvalYear":"1939","relationship":"same-class"},{"drugId":"plerixafor","brandName":"plerixafor","genericName":"plerixafor","approvalYear":"2008","relationship":"same-class"},{"drugId":"elapegademase","brandName":"elapegademase","genericName":"elapegademase","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04571229","phase":"","title":"Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma","status":"AVAILABLE","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"","conditions":["Osteosarcoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT03643133","phase":"PHASE2","title":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-10-23","conditions":["Osteosarcoma"],"enrollment":60,"completionDate":"2033-10"},{"nctId":"NCT03737435","phase":"","title":"Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study","status":"COMPLETED","sponsor":"Istituto Ortopedico Rizzoli","startDate":"2018-12-12","conditions":["Localized Osteosarcoma"],"enrollment":80,"completionDate":"2024-10-25"},{"nctId":"NCT01459484","phase":"PHASE2","title":"ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06-23","conditions":["Osteosarcoma"],"enrollment":225,"completionDate":"2024-04-30"},{"nctId":"NCT04383288","phase":"","title":"ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities","status":"COMPLETED","sponsor":"Grupo Espanol de Investigacion en Sarcomas","startDate":"2014-07-02","conditions":["Osteosarcoma"],"enrollment":115,"completionDate":"2020-10-17"},{"nctId":"NCT02441309","phase":"PHASE2","title":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2014-10","conditions":["Osteosarcoma"],"enrollment":8,"completionDate":"2016-11-04"},{"nctId":"NCT01194284","phase":"","title":"Surveillance Study of Patients With Newly Diagnosed Osteosarcoma","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2011-12","conditions":["Osteosarcoma"],"enrollment":25,"completionDate":"2013-12"},{"nctId":"NCT00631631","phase":"","title":"Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2008-01","conditions":["Osteosarcoma"],"enrollment":205,"completionDate":"2012-10"}],"_emaApprovals":[{"date":"2009-03-06","status":"Authorised","company":"Takeda France SAS"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"013385","UNII":"1LM890Q4FY","CHEBI":"CHEBI:135906","UMLSCUI":"C0129341","chemblId":"CHEMBL2107354","ChEMBL_ID":"CHEMBL2111100","KEGG_DRUG":"D06619","DRUGBANK_ID":"DB13615","PUBCHEM_CID":"11672602","SNOMEDCT_US":"710284002","IUPHAR_LIGAND_ID":"8274","SECONDARY_CAS_RN":"838853-48-8","MESH_SUPPLEMENTAL_RECORD_UI":"C037144"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Takeda France SAS","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.05 hours","clearance":"48.7 mL/min/kg","volumeOfDistribution":"5.8 L/kg"},"publicationCount":68,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L03AX15","allCodes":["L03AX15"]},"biosimilarFilings":[],"originalDeveloper":"Takeda France SAS","recentPublications":[{"date":"2026 Jan 14","pmid":"41534017","title":"Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"date":"2026 Jan 14","pmid":"41534000","title":"Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"date":"2025 Sep 17","pmid":"40960554","title":"The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide.","journal":"Medical oncology (Northwood, London, England)"},{"date":"2025 Oct","pmid":"40825172","title":"Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"date":"2025 Sep 15","pmid":"40711479","title":"Tumor Immune Microenvironment-Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Takeda France SAS","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"2009","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:22:20.117429+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}